Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Coverage Of Arthroscopic Knee Surgery Supported By Surgeon Groups

This article was originally published in The Gray Sheet

Executive Summary

Surgeon groups will submit a report to CMS Dec. 16 in support of national Medicare coverage for arthroscopic lavage and/or debridement of dysfunctional osteo-arthritic knee joints

You may also be interested in...



Arthroscopic Knee Surgery Coverage Guidelines Needed For Carriers – AAOS

The American Academy of Orthopaedic Surgeons hopes to meet with CMS to develop guidelines stipulating when local contractors should cover arthroscopic debridement indications for patients with osteoarthritis of the knee, following a 1July 3 non-coverage decision memorandum

Arthroscopic Knee Surgery Coverage Guidelines Needed For Carriers – AAOS

The American Academy of Orthopaedic Surgeons hopes to meet with CMS to develop guidelines stipulating when local contractors should cover arthroscopic debridement indications for patients with osteoarthritis of the knee, following a 1July 3 non-coverage decision memorandum

J&J/Cordis Previews Cypher Cost Benefit Data, Presses Cath Lab Savings

The cost-effectiveness ratio for using Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent is approximately $5,471 at nine months to one year compared with bare metal stents, according to data to be presented to the American College of Cardiology in March

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel